RHYTHM PHARMACEUTICALS, INC. Shareholders' Equity
RHYTHM PHARMACEUTICALS, INC. (RYTM) had Shareholders' Equity of $102.98 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity Attributable to Parent $102.98M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $122.91M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $139.07M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $148.82M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $102.98M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $122.91M 10-Q · filed 2026-08-04 |
| 2025-12-31 | $139.07M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $148.82M 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$11.91M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $18.95M 10-Q · filed 2026-08-04 |
| 2024-12-31 | $21.73M 10-Q · filed 2026-08-04 |
| 2024-09-30 | $11.21M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $39.34M 10-Q · filed 2025-11-04 |
| 2024-03-31 | $61.58M 10-Q · filed 2025-11-04 |
| 2023-12-31 | $169.76M 10-K · filed 2026-02-26 |
| 2023-09-30 | $197.47M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $182.28M 10-Q · filed 2024-11-06 |
| 2023-03-31 | $219.76M 10-Q · filed 2024-11-06 |
| 2022-12-31 | $264.26M 10-K · filed 2026-02-26 |
| 2022-09-30 | $281.19M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $195.63M 10-Q · filed 2023-11-08 |
| 2022-03-31 | $235.77M 10-Q · filed 2023-11-08 |
| 2021-12-31 | $284.15M 10-K · filed 2025-02-28 |
| 2021-09-30 | $322.26M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $351.69M 10-Q · filed 2022-11-08 |
| 2021-03-31 | $380.95M 10-Q · filed 2022-11-08 |
| 2020-12-31 | $166.53M 10-K · filed 2024-02-29 |
| 2020-09-30 | $196.94M 10-Q · filed 2021-11-02 |
| 2020-06-30 | $225.75M 10-Q · filed 2021-11-02 |
| 2020-03-31 | $253.10M 10-Q · filed 2021-11-02 |
| 2019-12-31 | $281.02M 10-K · filed 2023-03-01 |
| 2019-09-30 | $149.12M 10-Q · filed 2020-11-02 |
| 2019-06-30 | $181.47M 10-Q · filed 2020-11-02 |
| 2019-03-31 | $220.49M 10-Q · filed 2020-11-02 |
| 2018-12-31 | $246.26M 10-K · filed 2022-03-01 |
| 2018-09-30 | $269.64M 10-Q · filed 2019-11-01 |
| 2018-06-30 | $284.32M 10-Q · filed 2019-11-01 |
| 2018-03-31 | $133.66M 10-Q · filed 2019-11-01 |
| 2017-12-31 | $144.79M 10-K · filed 2021-03-01 |
| 2017-09-30 | -$51.86M 10-Q · filed 2017-11-14 |
| 2016-12-31 | -$32.70M 10-K · filed 2020-03-02 |
| 2015-12-31 | -$8.00M 10-K · filed 2019-03-08 |
| 2014-12-31 | -$358.00K 8-K · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |